Chaozeng Si

Chaozeng Si

Auto-generated profile, based on publicly available information

Chaozeng Si

Department of information management, China-Japan Friendship Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cell Reports
Verified
Journal Article
Open access
ZAZhaojun An
Zhaojun An
PLPeng Liu
Peng Liu
JZJiashun Zheng
Jiashun Zheng
CSChaozeng Si
Chaozeng Si
TLTianda Li
Tianda Li
SDSheng Ding
Sheng Ding
Ectopic expression of Oct4, Sox2, Klf4, and c-Myc can reprogram differentiated somatic cells into induced pluripotent stem cells (iPSCs). For years, Oct4 has been considered the key reprogramming factor core of the four factors. Here, we challenge this view by reporting a core function of Sox2 and Klf4 in reprogramming. We found that polycistronic expression of Sox2 and Klf4 was sufficient to induce pluripotency in the absence of exogenous Oct4, and the stoichiometry of Sox2 and Klf4 was essential. Sox2 and Klf4 cooperatively bound across the genome, leading to epigenetic remodeling of their targets, including pluripotency genes and gradual activation of the pluripotency network. Interestingly, cells of different germ layer origins, fibroblasts (mesoderm) and neural progenitor cells (ectoderm), showed convergent reprogramming trajectories and similar efficiency. This work demonstrates a core function of Sox2 and Klf4 in pluripotency induction and shows that this mechanism is independent of germ layer origin.

21 November 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
ZCZhiheng Cheng
Zhiheng Cheng
YDYifeng Dai
Yifeng Dai
YPYifan Pang
Yifan Pang
YJYang Jiao
Yang Jiao
YLYan Liu
Yan Liu
LFLin Fu
Lin Fu
The mammalian target of rapamycin (mTOR) inhibitor, DNA damage inducible transcript 4 (DDIT4), has inducible expression in response to various cellular stresses. In multiple malignancies, studies have shown that DDIT4 participates in tumorigenesis and impacts patient survival. We aimed to study the prognostic value of DDIT4 in acute myeloid leukaemia (AML), which is currently unclear. Firstly, The Cancer Genome Atlas was screened for AML patients with complete clinical characteristics and DDIT4 expression data. A total of 155 patients were included and stratified according to the treatment modality and the median DDIT4 expression levels. High DDIT4 expressers had shorter overall survival (OS) and event‐free survival (EFS) than the low expressers among the chemotherapy‐only group (all P < .001); EFS and OS were similar in the high and low DDIT4 expressers of the allogeneic haematopoietic stem cell transplantation (allo‐HSCT) group. Furthermore, in the DDIT4high group, patients treated with allo‐HSCT had longer EFS and OS than those who received chemotherapy alone (all P < .01). In the DDIT4low group, OS and EFS were similar in different treatment groups. Secondly, we analysed two other cytogenetically normal AML (CN‐AML) cohorts derived from the Gene Expression Omnibus database, which confirmed that high DDIT4 expression was associated with poorer survival. Gene Ontology (GO) enrichment analysis showed that the genes related to DDIT4 expression were mainly concentrated in the acute and chronic myeloid leukaemia signalling pathways. Collectively, our study indicates that high DDIT4 expression may serve as a poor prognostic factor for AML, but its prognostic effects could be outweighed by allo‐HSCT.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
LFLin Fu
Lin Fu
ZCZhiheng Cheng
Zhiheng Cheng
FDFen Dong
Fen Dong
LQLiang Quan
Liang Quan
LCLongzhen Cui
Longzhen Cui
CSChaozeng Si
Chaozeng Si
Background: Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE receptor Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have shown that FCER1G participates in many immune-related pathways encompassing multiple cell types. Meanwhile, it is associated with many malignancies. However, the relationship between MM and FCER1G has not been studied.

6 January 2020 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
TQTingting Qian
Tingting Qian
LCLongzhen Cui
Longzhen Cui
YLYan Liu
Yan Liu
ZCZhiheng Cheng
Zhiheng Cheng
LQLiang Quan
Liang Quan
CSChaozeng Si
Chaozeng Si

17 June 2019 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
YDYifeng Dai
Yifeng Dai
ZCZhiheng Cheng
Zhiheng Cheng
YPYifan Pang
Yifan Pang
YJYang Jiao
Yang Jiao
TQTingting Qian
Tingting Qian
LFLin Fu
Lin Fu

24 March 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ZCZhiheng Cheng
Zhiheng Cheng
YDYifeng Dai
Yifeng Dai
TZTiansheng Zeng
Tiansheng Zeng
YLYan Liu
Yan Liu
LCLongzhen Cui
Longzhen Cui
LFLin Fu
Lin Fu
One of the key features of acute myeloid leukemia (AML), a group of very aggressive myeloid malignancies, is their strikingly heterogenous outcomes. Accurate biomarkers are needed to improve prognostic assessment. Glutamate oxaloacetate transaminase 1 (GOT1) is essential for cell proliferation and apoptosis by regulating cell's metabolic dependency on glucose. It is unclear whether the expression level of GOT1 has clinical implications in AML. Therefore, we analyzed the data of 155 AML patients with GOT1 expression information from The Cancer Genome Atlas (TCGA) database. Among them, 84 patients were treated with chemotherapy alone, while 71 received allogeneic hematopoietic stem cell transplantation (allo-HSCT). In both treatment groups, high GOT1 expression was associated with shorter event-free survival (EFS) and overall survival (OS) (all P < 0.05). Multivariate analysis identified several independent risk factors for both EFS and OS in the chemotherapy-only group, including high GOT1 expression, age ≥60 years, white blood cell count ≥15 × 109/L, bone marrow blasts ≥70%, and DNMT3A, RUNX1 or TP53 mutations (all P < 0.05); but in the allo-HSCT group, the only independent risk factor for survival was high GOT1 expression (P < 0.05 for both EFS and OS). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that the genes related to GOT1 expression were mainly concentrated in “hematopoietic cell lineage” and “leukocyte transendothelial migration” signaling pathways. Collectively, GOT1 expression may be a useful prognostic indicator in AML, especially in patients who have undergone allo-HSCT.